ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,683.57
      1.26%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. CASI Pharmaceuticals Inc (CASI)

      7. CASI Pharmaceuticals Inc (CASI) News

      CASI

      CASI Pharmaceuticals (CASI)

      CASI Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CASI
      DateTimeSourceHeadlineSymbolCompany
      04/08/20245:00PMPR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
      03/28/20247:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
      03/05/20247:00AMPR Newswire (US)CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaNASDAQ:CASICASI Pharmaceuticals Inc
      02/16/20247:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
      11/14/20237:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
      11/08/20237:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPANASDAQ:CASICASI Pharmaceuticals Inc
      08/11/20237:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
      08/01/20237:00AMPR Newswire (US)Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsNASDAQ:CASICASI Pharmaceuticals Inc
      07/20/20238:00AMPR Newswire (US)CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339NASDAQ:CASICASI Pharmaceuticals Inc
      05/17/20237:35AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
      04/26/20239:49AMPR Newswire (US)CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022NASDAQ:CASICASI Pharmaceuticals Inc
      04/26/20238:27AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CASICASI Pharmaceuticals Inc
      04/26/20237:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
      03/22/20236:04AMEdgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CASICASI Pharmaceuticals Inc
      03/21/20235:08PMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CASICASI Pharmaceuticals Inc
      03/21/20234:51PMEdgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CASICASI Pharmaceuticals Inc
      03/21/20234:42PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
      03/21/20234:30PMPR Newswire (US)CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGERNASDAQ:CASICASI Pharmaceuticals Inc
      02/09/202310:49AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
      02/01/202310:40AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
      01/31/20234:02PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
      01/06/20237:00AMPR Newswire (US)CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
      12/15/20227:00AMPR Newswire (US)CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNASDAQ:CASICASI Pharmaceuticals Inc
      11/16/20222:57AMTipRanksBTIG Sticks to Their Buy Rating for CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
      11/14/20224:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
      11/14/20227:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
      09/28/20226:25AMTipRanksH.C. Wainwright Remains a Buy on CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
      09/23/20227:00AMPR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETNASDAQ:CASICASI Pharmaceuticals Inc
      09/09/20224:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CASICASI Pharmaceuticals Inc
      09/07/20227:00AMPR Newswire (US)CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:CASI